Company Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases.
The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer.
It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer.
The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Country | United States |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Contact Details
Address: 107 Spring Street Seattle, Washington United States | |
| Website | https://www.atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001488039 |
| CUSIP Number | 04962H506 |
| ISIN Number | US04962H5063 |
| Employer ID | 26-4753208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer & President |
| Heather Rees CPA | Chief Financial Officer |
| Delly Behen P.H.R. | Senior Vice President of Administration & HR |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
| Michael Parks | Vice President of Investor & Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 424B5 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |